Bossotel® is indicated for reducing postprandial blood glucose in people with low glucose tolerance and type 2 diabetes.
Bossotel ® is a first-line drug recommended by the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition)", and has been included in the National Essential Drugs List and the National Medical Insurance Directory.
Acarbose is an α-glucosidase inhibitor (AGI), AGI has the highest sales among oral hypoglycemic agents in China.
Due to the stable and reliable source of API, Boshutai® has a cost advantage.
Boshutai® was successfully selected in the 13 provinces alliance procurement in 2022, which brings new opportunities for future development.
China is the world's largest diabetes country, According to the Frost & Sullivan report, in 2020, the prevalence of diabetes among Chinese adults was as high as 11.9%, and the prevalence in 2016 was 10.8%. The number of people with diabetes is expected to exceed 140 million in 2022.
Due to the late entry of new drugs such as GLP-1 receptor agonists into the Chinese market, traditional chemical oral hypoglycemic drugs still occupy the largest market share in my country's diabetes treatment drugs.